Summary

Globally, millions of people are affected by neurological disorders. In that, over 80% of the death takes place in the low and middle-income countries. Worldwide Epilepsy is the most common neurological disorder, affecting people of all ages. This disease is a chronic brain disorder characterized by sudden and recurrent episodes of seizure. Patients who have epilepsy suffer from sudden behavioral changes, loss of consciousness and severe emotional distress. According to the World Health Organization (WHO), around 50 million people have epilepsy worldwide. Epilepsy is a common serious, and about 2.4 million new cases are diagnosed annually.

Besides, the rising incidence of higher birth-related injuries, neurological disorders, increasing road traffic injuries, growing disease awareness, and rising patient base in developing countries are the significant factors driving the global Epilepsy drug market. Increasing R&D investment and the launch of extended-release formulations are further expected to fuel the market growth. According to Renub Research, the Global Epilepsy Drugs Market is projected to reach US$ 10.3 Billion by 2027.

Globally, United States is the largest epilepsy drug market due to better healthcare infrastructure and rising cases of epilepsy. As per the Epilepsy Foundation of Michigan, epilepsy is the fourth most common neurological disorder in the United States after stroke, migraine, and Alzheimer’s disease. About one percent of Americans have some form of epilepsy, and nearly four percent (which is equal to 1 in 26) will develop epilepsy at some point in their lives. Thus, there is a rising demand for effective treatment in the US, significantly boosting the growth of the epilepsy drug market.

Additionally, China, India, and Brazil were among the countries with a higher proportion of the population suffering from the condition. To minimize the burden of this disease and facilitate the availability of better treatment options, governments from various countries across the world are providing active support. According to this research report, the Global Epilepsy Drugs Industry is likely to grow at a CAGR of 5.46% during (2020- 2027).

Based on Drugs Category
The global epilepsy drugs market is segmented into First Generation, Second Generation, Third Generation, Others. The third Generation holds the largest market share; the major factors responsible for the growth of the third generation segment include the launch of highly efficacy drugs with the enhanced mechanism of action, fewer side effects and the awaited launch of new pipeline medicines. Third-generation drugs such as Vimpat, Briviact and others have penetrated the worldwide market considerably and proven to be quite effective in treating epilepsy.

On the other hand, the second-generation antiepileptic drug class, including Keppra, Fycompa and Briviact. They dominated the market due to their large tolerability and safety due to the launch of highly potent drugs, which apply novel techniques mechanisms of action. Worldwide Epilepsy Drugs Market Size was US$ 7.1 Billion in 2020.

Top players such as Eisai Co., Ltd., UCB Inc., H. Lundbeck A/S, and GW Pharmaceuticals Plc. of Epilepsy Drugs Market focus on introducing medications that have lesser side-effects to the patients. Besides, companies are also focused on improving the potentiality of the drugs to control the symptoms of epilepsy effectively. In 2020, Eisai Co., Ltd. announced the launch of FYCOMPA in China to treat patients aged 12 years and more adults with partial-onset seizures.

Renub Research latest report “Global Epilepsy Drugs Market by Country (United States, United Kingdom, France, Germany, Italy, Spain, India, China, Japan) by Drugs Category (First Generation, Second Generation, Third Generation and Others) by Drugs (Vimpat (Lacosamide), Keppra (Levetiracetam), Sabril (Vigabatrin), Onfi (Clobazam), Fycompa Briviact (Brivaracetam), Epidiolex, Cenobamate (YKP3089) and Others) Company Analysis (Eisai Co., Ltd., UCB Inc., H. Lundbeck A/S, GW Pharmaceuticals Plc.)” Provides a detailed analysis Global Epilepsy Drugs Industry.

Country - Global Epilepsy Drugs Market have been covered from 9 Viewpoints:
1. United States
2. United Kingdom
3. France
4. Germany
5. Italy
6. Spain
7. India
8. China
9. Japan

Drugs Category - Global Epilepsy Drugs Market have been covered from 4 Viewpoints:
1. First Generation
2. Second Generation
3. Third Generation
4. Others

Drugs - Global Epilepsy Drugs Market have been covered from 9 Viewpoints:
1. Vimpat (Lacosamide)
2. Keppra (Levetiracetam)
3. Sabril (Vigabatrin)
4. Onfi (Clobazam)
5. Fycompa
6. Briviact (Brivaracetam)
7. Epidiolex
8. Cenobamate (YKP3089)
9. Others

Company Insights:
• Overview
• Company Initiatives
• Sales Analysis

Companies Covered:
1. Eisai Co., Ltd.
2. UCB Inc.
3. H. Lundbeck A/S
4. GW Pharmaceuticals Plc.

ページTOPに戻る

Table of Contents

1. Introduction

2. Research & Methodology

3. Executive Summary

4. Market Dynamics
4.1 Growth Drivers
4.2 Challenges

5. Global Epilepsy Drugs Market

6. Market Share – Global Epilepsy Drugs
6.1 By Country
6.2 By Drugs Category
6.3 By Drugs

7. Country - Global Epilepsy Drugs Market Analysis
7.1 United States
7.2 United Kingdom
7.3 France
7.4 Germany
7.5 Italy
7.6 Spain
7.7 India
7.8 China
7.9 Japan

8. Drugs Category - Global Epilepsy Drugs Market Analysis
8.1 First Generation
8.2 Second Generation
8.3 Third Generation
8.4 Others

9. Drugs - Global Epilepsy Drugs Market Analysis
9.1 Vimpat (Lacosamide)
9.2 Keppra (Levetiracetam)
9.3 Sabril (Vigabatrin)
9.4 Onfi (Clobazam)
9.5 Fycompa
9.6 Briviact (Brivaracetam)
9.7 Epidiolex
9.8 Cenobamate (YKP3089)
9.9 Others

10. Company Analysis
10.1 Eisai Co., Ltd.
10.1.1 Overview
10.1.2 Recent Development
10.1.3 Sales Analysis

10.2 UCB Inc.
10.2.1 Overview
10.2.2 Recent Development
10.2.3 Sales Analysis

10.3 H. Lundbeck A/S
10.3.1 Overview
10.3.2 Recent Development
10.3.3 Sales Analysis

10.4 GW Pharmaceuticals Plc.
10.4.1 Overview
10.4.2 Recent Development
10.4.3 Sales Analysis

Table-01: Global Epilepsy Drugs Market Share by Country (Percent), 2017 – 2020
Table-02: Forecast for – Global Epilepsy Drugs Market Share by Country (Percent), 2021 – 2027
Table-03: Global Epilepsy Drugs Market Share by Drugs Category (Percent), 2017 – 2020
Table-04: Forecast for – Global Epilepsy Drugs Market Share by Drugs Category (Percent), 2021 – 2027
Table-05: Global Epilepsy Drugs Market Share by Drugs (Percent), 2017 – 2020
Table-06: Forecast for – Global Epilepsy Drugs Market Share by Drugs (Percent), 2021 – 2027

Figure-01: Global Epilepsy Drugs Market (Million US$), 2017 – 2020
Figure-02: Forecast for – Global Epilepsy Drugs Market (Million US$), 2021 – 2027
Figure-03: United States – Epilepsy Drugs Market (Million US$), 2016 – 2020
Figure-04: United States – Forecast for Epilepsy Drugs Market (Million US$), 2021 – 2027
Figure-05: United Kingdom – Epilepsy Drugs Market (Million US$), 2016 – 2020
Figure-06: United Kingdom – Forecast for Epilepsy Drugs Market (Million US$), 2021 – 2027
Figure-07: France – Epilepsy Drugs Market (Million US$), 2016 – 2020
Figure-08: France – Forecast for Epilepsy Drugs Market (Million US$), 2021 – 2027
Figure-09: Germany – Epilepsy Drugs Market (Million US$), 2016 – 2020
Figure-10: Germany – Forecast for Epilepsy Drugs Market (Million US$), 2021 – 2027
Figure-11: Italy – Epilepsy Drugs Market (Million US$), 2016 – 2020
Figure-12: Italy – Forecast for Epilepsy Drugs Market (Million US$), 2021 – 2027
Figure-13: Spain – Epilepsy Drugs Market (Million US$), 2016 – 2020
Figure-14: Spain – Forecast for Epilepsy Drugs Market (Million US$), 2021 – 2027
Figure-15: India – Epilepsy Drugs Market (Million US$), 2016 – 2020
Figure-16: India – Forecast for Epilepsy Drugs Market (Million US$), 2021 – 2027
Figure-17: China – Epilepsy Drugs Market (Million US$), 2016 – 2020
Figure-18: China – Forecast for Epilepsy Drugs Market (Million US$), 2021 – 2027
Figure-19: Japan – Epilepsy Drugs Market (Million US$), 2016 – 2020
Figure-20: Japan – Forecast for Epilepsy Drugs Market (Million US$), 2021 – 2027
Figure-21: Drugs Category – First Generation Market (Million US$), 2016 – 2020
Figure-22: Drugs Category – Forecast for First Generation Market (Million US$), 2021 – 2027
Figure-23: Drugs Category – Second Generation Market (Million US$), 2016 – 2020
Figure-24: Drugs Category – Forecast for Second Generation Market (Million US$), 2021 – 2027
Figure-25: Drugs Category – Third Generation Market (Million US$), 2016 – 2020
Figure-26: Drugs Category – Forecast for Third Generation Market (Million US$), 2021 – 2027
Figure-27: Drugs Category – Others Market (Million US$), 2016 – 2020
Figure-28: Drugs Category – Forecast for Others Market (Million US$), 2021 – 2027
Figure-29: Drugs – Vimpat (Lacosamide) Market (Million US$), 2016 – 2020
Figure-30: Drugs – Forecast for Vimpat (Lacosamide) Market (Million US$), 2021 – 2027
Figure-31: Drugs – Keppra (Levetiracetam) Market (Million US$), 2016 – 2020
Figure-32: Drugs – Forecast for Keppra (Levetiracetam) Market (Million US$), 2021 – 2027
Figure-33: Drugs – Sabril (Vigabatrin) Market (Million US$), 2016 – 2020
Figure-34: Drugs – Forecast for Sabril (Vigabatrin) Market (Million US$), 2021 – 2027
Figure-35: Drugs – Onfi (Clobazam) Market (Million US$), 2016 – 2020
Figure-36: Drugs – Forecast for Onfi (Clobazam) Market (Million US$), 2021 – 2027
Figure-37: Drugs – Fycompa Market (Million US$), 2016 – 2020
Figure-38: Drugs – Forecast for Fycompa Market (Million US$), 2021 – 2027
Figure-39: Drugs – Briviact (Brivaracetam) Market (Million US$), 2016 – 2020
Figure-40: Drugs – Forecast for Briviact (Brivaracetam) Market (Million US$), 2021 – 2027
Figure-41: Drugs – Epidiolex Market (Million US$), 2018 – 2020
Figure-42: Drugs – Forecast for Epidiolex Market (Million US$), 2021 – 2027
Figure-43: Drugs – Cenobamate (YKP3089) Market (Million US$), 2019 – 2020
Figure-44: Drugs – Forecast for Cenobamate (YKP3089) Market (Million US$), 2021 – 2027
Figure-45: Drugs – Others Market (Million US$), 2016 – 2020
Figure-46: Drugs – Forecast for Others Market (Million US$), 2021 – 2027